Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jasper Therapeutics ( (JSPR) ) has shared an announcement.
On January 8, 2026, Jasper Therapeutics reported positive updated clinical results for briquilimab in chronic urticaria, with new Phase 1b/2a BEACON data in adults with CSU and longer-term outcomes from an open-label extension study in CSU and CIndU. In the BEACON trial’s 240mg/180mg Q8W cohort, 83% of briquilimab-treated patients achieved complete response by week 3 and 67% maintained complete response at 12 weeks, with a mean UAS7 reduction of 31 points and no dose-limiting toxicities. The open-label extension showed similarly robust outcomes on a 180mg Q8W regimen, with 58% of CSU patients achieving complete response and 75% achieving at least well-controlled disease at 12 weeks, while 65% of CIndU patients reached complete or partial response by week 16; across 63 patients and a median 205 days of follow-up, KIT-related adverse events were infrequent, low grade and resolved on treatment. The company said the combined efficacy and safety data from these studies are now sufficient to select dosing for a planned Phase 2b study in CSU in the second half of 2026, reinforcing briquilimab’s potential differentiated profile in the competitive chronic urticaria market and signaling a key step toward late-stage development that could be meaningful for patients and investors if confirmed in larger trials.
The most recent analyst rating on (JSPR) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Jasper Therapeutics stock, see the JSPR Stock Forecast page.
Spark’s Take on JSPR Stock
According to Spark, TipRanks’ AI Analyst, JSPR is a Neutral.
The score is held down primarily by weak financials (no revenue, widening losses, and significant cash burn with a shrinking equity cushion). Technicals also lean bearish with the stock below major moving averages. Offsetting these, a notable positive corporate event (encouraging Phase 1b results and clarified BEACON findings) provides some upside, but valuation remains difficult to support given ongoing losses and no dividend.
To see Spark’s full report on JSPR stock, click here.
More about Jasper Therapeutics
Jasper Therapeutics, Inc., based in Redwood City, California, is a clinical-stage biotechnology company developing briquilimab, an aglycosylated monoclonal antibody that blocks stem cell factor from binding to the KIT (CD117) receptor. The company focuses on treating chronic mast cell–driven diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, and is running multiple clinical trials to establish briquilimab’s efficacy and safety across these indications.
Average Trading Volume: 1,565,814
Technical Sentiment Signal: Sell
Current Market Cap: $53.17M
For detailed information about JSPR stock, go to TipRanks’ Stock Analysis page.